4. Copstead-Kirkhorn LE, Banasik JL. Pathophysiology. 6th ed. St. Louis, MO: Elsevier Health Sciences; 2019.
5. Mitchell R. Pocket Companion to Robbins and Cotran Pathologic Basis of Disease. 9th ed. Philadelphia, PA: Elsevier; 2017.
6. Avram M, Kiahr S. Renal Disease Progression and Management: Role of Vasoactive Agents, Cytokines, Lipids, and Nutrition. Philadelphia, PA: Elsevier Health Sciences; 1996.
8. Xin JZ, Laszidk ZG, Nadasdy T, D'Agati VD. Silva's Diagnostic Renal Pathology. 2nd ed. Cambridge: Cambridge University Press; 2018.
10. Nowak T. Pathophysiology: Concepts and Applications for Health Care Professionals. 2nd ed. Boston, MA: McGraw-Hill; 1999.
11. Rennke H, Denton M, Magee C. Renal Disease: Prevention and Treatment. New York, NY: CRC Press; 1998.
12. Johnson G. On the Diseases of the Kidney, Their Pathology, Diagnosis, and Treatment. London: J.W. Parker and Son; 1852.
13. Clark WB. The Diagnosis and Treatment of Diseases of the Kidney Amenable to Direct Surgical Interference. London: Lewis Publishing; 1886.
14. Wilcox CS. Therapy in Nephrology and Hypertension: A Companion to Brenner and Rector's The Kidney. 3rd ed. Philadelphia, PA: Saunders/Elsevier; 2008.
15. Moorthy V. Pathophysiology of Kidney Disease and Hypertension. Philadephia, PA: Elsevier Health Sciences; 2009.
16. Brenner BM, Coe FL, Rector FC. Renal Physiology in Health and Disease. Philadelphia, PA: Elsevier Health Sciences; 1987.
17. Gonick HC, Buckalew VM. Renal Tubular Disorders: Pathophysiology, Diagnosis and Management. New York, NY: Marcel Dekker; 1985.
20. McCance KL, Felver L. Pathophysiology: The Biologic Basis for Disease in Adults and Children. 8th ed. St. Louis, MO: Elsevier Health Sciences; 2018.
22. Humes HD. Pathophysiology of Electrolyte and Renal Disorders. New York, NY: Churchill Livingstone; 1986.
23. Tisher CC, Brenner BM. Renal Pathology with Clinical and Functional Correlations. 2nd ed. Philadelphia, PA: Lippincott, Williams, and Wilkins; 1994.
24. Price SA. Pathophysiology: Clinical Concepts of Disease Processes. 7th ed. St. Louis, MO: Mosby; 2014.
26. Brashers VL. Clinical Applications of Pathophysiology: Assessment, Diagnostic Reasoning and Management. 2nd ed. St. Louis, MO: Mosby; 2002.
27. Black J, Hawks JH, Keene AM. Medical Surgical Nursing: Clinical Management for Continuity of Care. 8th ed. Philadelphia, PA: W.B Saunders, 2011.
28. LeMone P, Burke KM, Bauldoff G. Medical-Surgical Nursing: Critical Thinking in Patient Care. 5th ed. Upper Saddle River, NJ: Prentice Hall; 2014.
29. Ginès P. Ascites and Renal Dysfunction in Liver Disease: Pathogenesis, Diagnosis, and Treatment. Walden, MA: Blackwell; 2005.
30. Suki WN, Eknoyan G. The Kidney in Systemic Disease. New York, NY: Wiley, John and Sons, Inc.; 1981.
32. Al-Shaikh TM, Alkaseb KS, Mudawi MME, Yassin AYA, Habeballa RS, Alzain SD. Toxicological studies on commercial hair dye brand commonly used in Saudi Arabia: histological study of the liver, kidney, heart, and testis. J Basic Appl Zoology. 2018;79:22.
33. Ackley BJ, Ladwig GB, Flynn Makic MB, Martinez-Kratz MR, Zanotti M. Nursing Diagnosis Handbook: An Evidence-Based Guide to Planning Care. 12th ed. St. Louis, MO: Elsevier; 2020.
34. Ladwig GE, Ackley BJ, Flynn Makic MB, Martinez-Kratz MR, Zanotti M. Mosby's Guide to Nursing Diagnosis. 6th ed. St. Louis, MO: Elsevier; 2020.
36. Zerwekh, JG, Claborn JC, Gaglione T, Gameau AZ, Souter S. Mosby's Pharmacology Memory NoteCards: Visual, Mnemonic, and Memory Aids for Nurses. 3rd ed. Philadelphia, PA: Elsevier Mosby; 2011.
37. Mount DB, Pollak MR. Molecular and Genetic Basis of Renal Disease. Philadelphia, PA: Elsevier Health Sciences; 2008.
40. McDougal WS, Wein AJ, Kavoussi LR, Partin AW, Peters C. Campbell-Walsh Urology 11th Edition Review. 2nd ed. Philadelphia, PA: Elsevier; 2015.
41. Bihl GR, Petri M, Fine DM. Kidney biopsy in lupus nephritis: look before you leap. Nephrol Dial Transplant. 2006;21(7):1749-1752.
42. Blake MA, Sweeney AT. Pheochromocytoma. Available at https://emedicine.medscape.com/article/124059-overview. Last accessed August 6, 2020
43. Ferrell BR, Paice JA. Oxford Textbook of Palliative Nursing. 5th ed. New York, NY: Oxford University Press; 2019.
45. Lederer E, Alsauskas ZC, Mackelaite L, Nayak V. Hyperkalemia. Available at https://emedicine.medscape.com/article/240903-overview. Last accessed August 6, 2020.
46. Kasper DL, Braunwald E, Hauser S, Longo D, Jameson JL, Fauci AS. Harrison's Principles of Internal Medicine. 19th ed. New York, NY: McGraw-Hill; 2015.
48. Lexicomp Online. Available at https://online.lexi.com. Last accessed August 6, 2020.
49. Sterns RH, Rojas M, Bernstein P, Chennupati S. Ion-exchange resins for the treatment of hyperkalemia: are they safe and effective? J Am Soc Nephrol. 2010;21(5):733-735.
50. Tamargo J. New Drugs for the Treatment of Hyperkalemia in Patients Treated with Renin-Angiotensin-Aldosterone System Inhibitors: Hype or Hope? Available at https://www.discoverymedicine.com/Juan-Tamargo/2014/11/new-drugs-for-the-treatment-of-hyperkalemia-in-patients-treated-with-renin-angiotensin-aldosterone-system-inhibitors-hype-or-hope. Last accessed August 6, 2020.
52. DiPiro JT. Pharmacotherapy A Pathophysiologic Approach. 11th ed. New York, NY: McGraw Hill Medical; 2020.
53. Longo DL, Kasper DL, Jameson JL, et al. Harrison's Principles of Internal Medicine. 19th ed. New York, New York: McGraw-Hill; 2015.
54. Malhotra D, Tzamaloukas AH. Non-dialysis management of chronic renal failure. Med Clin North Am. 1997;81(3):749-766.
55. Skorecki K, Chertow GM, Marsden PA, Taal MW, Yu ASL. Brenner and Rector's The Kidney. 10th ed. Philadelphia, PA: Saunders; 2015.
56. International Society of Nephrology. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Available at https://kdigo.org/wp-content/uploads/2017/02/KDIGO_2012_CKD_GL.pdf. Last accessed August 6, 2020.
57. NKF KDOQI Clinical Practice Guidelines for Chronic Kidney Disease: Evaluation, Classification, and Stratification. Available at https://www.kidney.org/sites/default/files/docs/ckd_evaluation_classification_stratification.pdf. Last accessed August 6, 2020.
58. Centers for Medicare and Medicaid Services. Medicare Coverage of Kidney Dialysis and Kidney Transplant Services. Available at https://www.medicare.gov/Pubs/pdf/10128-Medicare-Coverage-ESRD.pdf. Last accessed November 5, 2018.
59. Centers for Disease Control and Prevention. National Chronic Kidney Disease Fact Sheet, 2017. Atlanta, GA: US Department of Health and Human Services; 2017.
60. Bullock A, Burrows NR, Narva AS, et al. Vital signs: decrease in incidence of diabetes-related end-stage renal disease among American Indians/Alaska Natives—United States, 1996–2013. MMWR. 2017;66(01):26-32.
61. Burrows NR, Li Y, Geiss LS. Incidence of treatment for end-stage renal disease among individuals with diabetes in the U.S. continues to decline. Diabetes Care. 2010;33(1):73-77.
62. Whaley-Connell AT, Vassalotti JA, Collins AJ, Chen SC, McCullough PA. National Kidney Foundation's Kidney Early Evaluation Program (KEEP) annual data report 2011: executive summary. Am J Kidney Dis. 2012;59(3 Suppl 2):S1-S4.
63. United States Renal Data System Annual Data Report 2018: Epidemiology of Kidney Disease in the United States. Available at https://www.usrds.org/adr.aspx. Last accessed August 6, 2020.
64. Gross ML, Dikow R, Ritz E. Diabetic nephropathy: recent insights into the pathophysiology and the progression of diabetic nephropathy. Kidney Int. 2005;(94):S50-S53.
65. Shumway JT, Gambert SR. Diabetic nephropathy: pathophysiology and management. Int Urol Nephrol. 2002;34(2):257-264.
66. UK Prospective Diabetes Study Group. Effect of intensive blood glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998;352(9131):854-865.
67. Jones J, Holmen J, De Graauw J, Jovanovich A, Thornton S, Chonchol M. Association of complete recovery from acute kidney injury with incident CKD stage 3 and all-cause mortality. Am J Kidney Dis. 2012;60(3):402-408.
68. Hart PD, Bakris GL. Hypertensive nephropathy: prevention and treatment recommendations. Expert Opin Pharmacother. 2010;11(16):2675-2686.
70. Portolés J, Gorriz JL, Rubio E, et al. The development of anemia is associated to poor prognosis in NKF/KDOQI stage 3 chronic kidney disease. BMC Nephrol. 2013;14:2.
71. National Kidney Foundation. KDOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease.Am J Kidney Dis. 2003;42(Suppl 3):S1-S201.
72. Sarafidis PA, Blacklock R, Wood E, et al. Prevalence and factors associated with hyperkalemia in predialysis patients followed in a low-clearance clinic. Clin Am J Soc Nephrol. 2012;7(8):1234-1241.
73. Block GA, Ix JH, Ketteler M, et al. Phosphate homeostasis in CKD: report of a scientific symposium sponsored by the National Kidney Foundation. Am J Kidney Dis. 2013;62(3):457-473.
74. Lanken PN, Terry PB, Delisser HM, et al. An official American Thoracic Society clinical policy statement: palliative care for patients with respiratory diseases and critical illnesses. Am J Respir Crit Care Med. 2008;177(8):912-927.
75. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345(12):851-860.
76. National Kidney Foundation. KDOQI clinical practice guidelines for chronic kidney disease: evaluation, classification and stratification. Am J Kidney Dis. 2002;39(Suppl 1):S1-S266.
77. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int. 2013;3:1-150.
78. American Dietetic Association. Manual of Clinical Dietetics. 6th ed. Chicago, IL: Academy of Nutrition and Dietetics; 2000.
79. London GM. Left ventricular alterations and end-stage renal disease. Nephrol Dial Transplant. 2002;17(1):S29-S36.
80. Workeneh BT, Agraharkar M, Gupta R. Acute Kidney Injury. Available at https://emedicine.medscape.com/article/243492-overview. Last accessed August 6, 2020.
81. Huether SE, McCance KL, Brashers VL. Understanding Pathophysiology. 7th ed. St. Louis, MO: Elsevier; 2020.
83. Baird MS. Manual ofCritical Care Nursing: Nursing Interventions and Collaborative Management. 7th ed. St. Louis, MO: Mosby; 2016.
84. Norris TL. Porth's Pathophysiology: Concepts of Altered Health States. 10th ed. Philadelphia, PA: Wolters Kluwer; 2019.
85. National Institute of Diabetes and Digestive and Kidney Diseases. National Kidney Disease Education Program. Available at https://www.niddk.nih.gov/health-information/community-health-outreach/information-clearinghouses/nkdep. Last accessed June 23, 2020.
87. Bruyere HJ Jr. 100 Case Studies in Pathophysiology. Philadelphia, PA: Lippincott, Williams and Wilkins: 2009.
88. Berg SM, Bittner EA, Lee J. Massachusetts General Hospital Review of Critical Care Medicine. Philadelphia, PA: Wolters, Kluwer, Lippincott, Williams & Wilkins; 2014.
89. American Cancer Society. Key Statistics About Kidney Cancer. Available at https://www.cancer.org/cancer/kidney-cancer/about/key-statistics.html. Last accessed August 6, 2020.
90. Smith S. Kidney Cancer: Causes, Symptoms, Signs, Diagnosis, Treatments, Stages of Kidney Cancer. Charleston, SC: CreateSpace; 2012.
91. American Cancer Society. Key Statistics About Bladder Cancer. Available at https://www.cancer.org/cancer/bladder-cancer/about/key-statistics.html. Last accessed August 6, 2020.
92. National Cancer Institute. Bladder Cancer Treatment (PDQ)–Health Professional Version. Available at https://www.cancer.gov/types/bladder/hp/bladder-treatment-pdq. Last accessed August 6, 2020.
93. Galvagno SM. Emergency Pathophysiology: Clinical Applications for Prehospital Care. Jackson, WY: Teton NewMedia; 2013.
95. Markovchick VJ, Pons PT, Bakes KM, Buchanan JA. Emergency Medicine Secrets. 6th ed. Philadelphia, PA: Elsevier; 2016.
96. Goldstein RS. Mechanisms of Injury in Renal Disease and Toxicity. Boca Raton, FL: CRC Press; 1994.
97. KDOQI Clinical Practice Guidelines for vascular access. Am J Kidney Dis. 2006;48(Suppl 1):S176-S247.
98. Beathard G. A practitioner's resource guide to hemodialysis arteriovenous fistulas. ESRD Network of Texas. 2003;(Suppl).
99. Lomonte C, Basile C. Preoperative assessment and planning of hemodialysis vascular access. Clin Kidney J. 2015;8(3):278-281.
100. Santoro D, Benedetto F, Mondello P, et al. Vascular access for hemodialysis: current perspectives. Int J Nephrol Renovasc Dis. 2014;7:284-294.
101. Drew DA, Lok CE. Strategies for planning the optimal dialysis access for an individual patient. Curr Opin Nephrol Hypertens. 2014;23(3):314-320.
102. Tordoir JH, Bode AS, van Loon MM. Preferred strategy for hemodialysis in access creation in elderly patients. Eur J Vasc Endovasc Surg. 2015;49(6):738-743.
103. Mansilla AV, Toombs BD, Vaughn WK, Zeledon JI. Patency and life-spans of failing hemodialysis grafts in patients undergoing repeated percutaneous de-clotting. Tex Heart Inst J. 2001;28(4):249-253.
104. Zaleski G. Declotting, maintenance, and avoiding procedural complications of native arteriovenous fistulae. Semin Intervent Radiol. 2004;21(2):83-93.
105. Centers for Medicare and Medicaid Services. Center for Clinical Standards and Quality. CMS ESRD Measured Manual for the 2018 Performance Period/2020 Payment Year v3.0. Available at https://www.cms.gov/Medicare/Quality-Initiatives-Patient-Assessment-Instruments/ESRDQIP/Downloads/ESRD-Manual-v30.pdf. Last accessed August 6, 2020.
106. Hagen SM, Lafranca JA, Ijzemans JN, Dor FJ. A systematic review and meta-analysis of the influence of peritoneal dialysis catheter type on complication rate and catheter survival. Kidney Int. 2014;85(4):920-932.
107. Lye WC, Kour NW, van der Straaten JC, Leong SO, Lee EJ. A prospective randomized comparison of the Swan neck, coiled, and straight Tenckhoff catheters in patients on CAPD. Perit Dial Int. 1996;16(Suppl 1):S333-S335.
108. Xie J, Kiryluk K, Ren H, et al. Coiled versus straight peritoneal dialysis catheters: a randomized controlled trial and meta-analysis. Am J Kidney Dis. 2011;58(6):946-955.
109. National Institute of Diabetes and Digestive and Kidney Diseases. Kidney Disease Statistics for the United States. Available at https://www.niddk.nih.gov/health-information/health-statistics/kidney-disease. Last accessed August 6, 2020.
110. Stock PG, Barin B, Murphy B, et al. Outcomes of kidney transplantation in HIV-infected recipients. N Engl J Med. 2010;363(21):2004-2014.
111. Organ Procurement and Transplantation Network. Policies: Allocation of Kidneys. Available at https://optn.transplant.hrsa.gov/media/1200/optn_policies.pdf. Last accessed August 6, 2020.
112. Organ Procurement and Transplantation Network. Kidney Allocation System. Available at https://optn.transplant.hrsa.gov/learn/professional-education/kidney-allocation-system. Last accessed August 6, 2020.
113. Tapiawala SN, Tinckam KJ, Cardella CJ, et al. Delayed graft function and the risk for death with a functioning graft. J Am Soc Nephrol. 2010;21(1):153-161.
114. Curtis JR. Palliative and end-of-life care for patients with severe COPD. Eur Respir J. 2008;32(3):796-803.
115. Renal Physicians Association. Shared Decision-Making in the Appropriate Initiation and Withdrawal from Dialysis. Clinical Practice Guideline. 2nd ed. Rockville, MD: Renal Physicians Association; 2010.
116. Larson AM, Curtis JR. Integrating palliative care for liver transplant candidates: "too well for transplant, too sick for life." JAMA. 2006;295(108):2168-2176.
117. McCusker M, Ceronsky L, Crone C, et al. Institute for Clinical Systems Improvement. Palliative Care for Adults. Available at https://www.icsi.org/_asset/k056ab/PalliativeCare.pdf. Last accessed August 6, 2020.
118. Clayton JM, Hancock KM, Butow PN, et al. Clinical practice guidelines for communicating prognosis and end-of-life issues with adults in the advanced stages of a life-limiting illness, and their caregivers. Med J Aust. 2007;188(12 Suppl):S77, S79, S83-S108.
119. Buckman R. Communication skills in palliative care: a practical guide. Neurol Clin. 2001;19(4):989-1004.
120. Finlay E, Casarett D. Making difficult decisions easier: using prognosis to facilitate transitions to hospice. Ca Cancer J Clin. 2009;59:250-263.
121. Stapleton R, Curtis JR. End-of-life considerations in older patients who have lung disease. Clin Chest Med. 2007;28(4):801-811.
1. Management of Chronic Kidney Disease Working Group. VA/DoD Clinical Practice Guideline for the Management of Chronic Kidney Disease in Primary Care. Washington, DC: Department of Veterans Affairs, Department of Defense; 2014. Available at https://www.healthquality.va.gov/guidelines/CD/ckd/VADoDCKDCPG2014.pdf. Last accessed August 14, 2020.
2. American Dietetic Association. Chronic Kidney Disease Evidence-Based Nutrition Practice Guideline. Chicago, IL: American Dietetic Association; 2010. Available at https://www.andeal.org/topic.cfm?cat=3927. Last accessed August 14, 2020.
3. Kasiske BL, Zeier MG, Chapman JR, et al. KDIGO clinical practice guideline for the care of kidney transplant recipients: a summary. Kidney Int. 2010;77(4):299-311. Available at https://kdigo.org/wp-content/uploads/2017/02/KDIGO-2009-Transplant-Recipient-Guideline-English.pdf. Last accessed August 14, 2020.
Mention of commercial products does not indicate endorsement.